{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:15:08Z","timestamp":1772165708239,"version":"3.50.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003385","name":"Georg-August-Universit\u00e4t G\u00f6ttingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003385","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Myasthenia gravis (MG) affects individuals as a chronic autoimmune disease for many years. Commonly, chronic diseases significantly reduce the patients\u2019 quality of life. Aiming to improve the future quality of life in MG, this study assessed the factors impacting quality of life. As gender-specific medicine is becoming increasingly important, this study also focused on understanding gender differences in the outcome of MG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study is a combined monocentric, retrospective and prospective database analysis of patient records based on 2,370 presentations of 165 patients with clinically, serologically and\/or electrophysiologically confirmed MG over an observation period of up to 47 years. The data collection included the following parameters: antibody status, disease severity, age, medication use, gender, and disease duration. In addition, a prospective survey was conducted on the quality of life using the Myasthenia gravis-specific 15-item Quality of Life scale (MG-QoL15) and on the activities of daily living using the MG-specific Activities of Daily Living scale (MG-ADL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 165 patients, 85 were male (51.5%) and 80 were female (48.5%). The remaining baseline characteristics (e.g. age and antibody status) were consistent with other myasthenia gravis cohorts. A high body mass index (BMI) (p\u2009=\u20090.005) and a high disease severity (p\u2009&lt;\u20090.001) were significantly associated with lower disease-specific quality of life. Additionally, the quality of life in women with MG was significantly reduced compared to male patients (19.7 vs. 13.0 points in the MG-QoL15, p\u2009=\u20090.024). Gender differences were also observable in terms of the period between initial manifestation and initial diagnosis and women were significantly more impaired in their activities of daily living (MG-ADL) than men (4.8 vs. 3.0 points, p\u2009=\u20090.032).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Women with MG had significantly poorer disease specific quality of life compared to men as well as patients with a higher BMI. In order to improve the quality of life, gender-specific medicine and further investigation regarding a modification of the quality of life by lowering the BMI are essential and necessary.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Study approval by the Ethics Committee of the University Medical Center G\u00f6ttingen was granted (number 6\/5\/18).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-023-03406-0","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T03:02:54Z","timestamp":1696906974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Female sex and overweight are associated with a lower quality of life in patients with myasthenia gravis: a single center cohort study"],"prefix":"10.1186","volume":"23","author":[{"given":"Hannah","family":"Wilcke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Glaubitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"K\u00fcck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Anten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Liebetanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Zsch\u00fcntzsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,10]]},"reference":[{"key":"3406_CR1","doi-asserted-by":"publisher","unstructured":"Salari N, Fatahi B, Bartina Y, Kazeminia M, Fatahian R, Mohammadi P, et al. Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis. J Transl Med. 2021;19(1):516. https:\/\/doi.org\/10.1186\/s12967-021-03185-7","DOI":"10.1186\/s12967-021-03185-7"},{"issue":"1\u20132","key":"3406_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2012.10.028","volume":"325","author":"MA Hellmann","year":"2013","unstructured":"Hellmann MA, Mosberg-Galili R, Steiner I. Myasthenia gravis in the elderly. J Neurol Sci. 2013;325(1\u20132):1\u20135.","journal-title":"J Neurol Sci"},{"issue":"3","key":"3406_CR3","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1093\/brain\/103.3.579","volume":"103","author":"DA Compston","year":"1980","unstructured":"Compston DA, Vincent A, Newsom-Davis J, Batchelor JR. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain J Neurol. 1980;103(3):579\u2013601.","journal-title":"Brain J Neurol"},{"key":"3406_CR4","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1196\/annals.1254.055","volume":"998","author":"JA Aarli","year":"2003","unstructured":"Aarli JA, Romi F, Skeie GO, Gilhus NE. Myasthenia gravis in individuals over 40. Ann N Y Acad Sci. 2003;998:424\u201331.","journal-title":"Ann N Y Acad Sci"},{"key":"3406_CR5","doi-asserted-by":"publisher","unstructured":"Schneider-Gold C, Hartung H-P. Myasthenia gravis: pathogenese, diagnostik und therapie. Fortschritte Neurol Psychiatr. 2004;72(1):45\u201357. https:\/\/doi.org\/10.1055\/s-2003-812457","DOI":"10.1055\/s-2003-812457"},{"issue":"26","key":"3406_CR6","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE. Myasthenia gravis. N Engl J Med. 2016;375(26):2570\u201381.","journal-title":"N Engl J Med"},{"issue":"4158","key":"3406_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1126\/science.186.4158.55","volume":"186","author":"RR Almon","year":"1974","unstructured":"Almon RR, Andrew CG, Appel SH. Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors. Science. 1974;186(4158):55\u20137.","journal-title":"Science"},{"issue":"8","key":"3406_CR8","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","volume":"263","author":"N Melzer","year":"2016","unstructured":"Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A, et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the guidelines of the German neurological society. J Neurol. 2016;263(8):1473\u201394.","journal-title":"J Neurol"},{"issue":"22","key":"3406_CR9","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1212\/WNL.0000000000000478","volume":"82","author":"C Gasperi","year":"2014","unstructured":"Gasperi C, Melms A, Schoser B, Zhang Y, Meltoranta J, Risson V, et al. Anti-agrin autoantibodies in myasthenia gravis. Neurology. 2014;82(22):1976\u201383.","journal-title":"Neurology"},{"issue":"6","key":"3406_CR10","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s00415-017-8514-z","volume":"264","author":"I Cordts","year":"2017","unstructured":"Cordts I, Bodart N, Hartmann K, Karagiorgou K, Tzartos JS, Mei L, et al. Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis. J Neurol. 2017;264(6):1193\u2013203.","journal-title":"J Neurol"},{"key":"3406_CR11","doi-asserted-by":"publisher","unstructured":"Kim KH, Kim SW, Cho J, Chung HY, Shin HY. Anti-titin antibody is associated with more frequent hospitalization to manage thymoma-associated myasthenia gravis. Front Neurol. 2022;13:978997. https:\/\/doi.org\/10.3389\/fneur.2022.978997\/full","DOI":"10.3389\/fneur.2022.978997\/full"},{"issue":"2","key":"3406_CR12","first-page":"CD002828","volume":"2005","author":"C Schneider-Gold","year":"2005","unstructured":"Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev. 2005;2005(2):CD002828.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"3406_CR13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0022-510X(97)05370-7","volume":"150","author":"MB Bromberg","year":"1997","unstructured":"Bromberg MB, Wald JJ, Forshew DA, Feldman EL, Albers JW. Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis. J Neurol Sci. 1997;150(1):59\u201362.","journal-title":"J Neurol Sci"},{"key":"3406_CR14","doi-asserted-by":"crossref","unstructured":"Piehl F, Eriksson-Dufva A, Budzianowska A, Feresiadou A, Hansson W, Hietala MA, et al. Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial. JAMA Neurol. 2022;79(11):1105. https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2796552","DOI":"10.1001\/jamaneurol.2022.2887"},{"issue":"4","key":"3406_CR15","first-page":"CD002275","volume":"2002","author":"P Gajdos","year":"2002","unstructured":"Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev. 2002;2002(4):CD002275.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"3406_CR16","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1602489","volume":"375","author":"GI Wolfe","year":"2016","unstructured":"Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, et al. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med. 2016;375(6):511\u201322.","journal-title":"N Engl J Med"},{"issue":"5","key":"3406_CR17","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/WCO.0000000000000858","volume":"33","author":"MC Dalakas","year":"2020","unstructured":"Dalakas MC. Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies. Curr Opin Neurol. 2020;33(5):545\u201352.","journal-title":"Curr Opin Neurol"},{"issue":"7","key":"3406_CR18","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1080\/1744666X.2022.2082946","volume":"18","author":"MC Dalakas","year":"2022","unstructured":"Dalakas MC. Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis. Expert Rev Clin Immunol. 2022;18(7):691\u2013701.","journal-title":"Expert Rev Clin Immunol"},{"issue":"8","key":"3406_CR19","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","volume":"82","author":"D Menon","year":"2022","unstructured":"Menon D, Bril V. Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals. Drugs. 2022;82(8):865\u201387.","journal-title":"Drugs"},{"issue":"12","key":"3406_CR20","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard","year":"2017","unstructured":"Howard JF, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976\u201386.","journal-title":"Lancet Neurol"},{"key":"3406_CR21","doi-asserted-by":"publisher","unstructured":"Muppidi S, Silvestri NJ, Tan R, Riggs K, Leighton T, Phillips GA. Utilization of MG-ADL in myasthenia gravis clinical research and care. Muscle Nerve. 2022;65(6):630\u20139. https:\/\/doi.org\/10.1002\/mus.27476","DOI":"10.1002\/mus.27476"},{"issue":"23","key":"3406_CR22","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","volume":"92","author":"JF Howard","year":"2019","unstructured":"Howard JF, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019;92(23):e2661\u201373.","journal-title":"Neurology"},{"key":"3406_CR23","doi-asserted-by":"publisher","unstructured":"P\u00f6llmann W, Busch C, Voltz R. Lebensqualit\u00e4t bei multipler sklerose: messinstrumente, bedeutung, probleme und perspektiven. Nervenarzt. 2005;76(2):154\u201369. https:\/\/doi.org\/10.1007\/s00115-004-1790-8","DOI":"10.1007\/s00115-004-1790-8"},{"issue":"3\u20134","key":"3406_CR24","first-page":"76","volume":"47","author":"M Bullinger","year":"1997","unstructured":"Bullinger M. [Health related quality of life and subjective health. Overview of the status of research for new evaluation criteria in medicine]. Psychother Psychosom Med Psychol. 1997;47(3\u20134):76\u201391.","journal-title":"Psychother Psychosom Med Psychol"},{"issue":"2","key":"3406_CR25","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1002\/mus.21053","volume":"38","author":"TM Burns","year":"2008","unstructured":"Burns TM, Conaway MR, Cutter GR, Sanders DB, Muscle Study Group. Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis. Muscle Nerve. 2008;38(2):957\u201363.","journal-title":"Muscle Nerve"},{"issue":"1","key":"3406_CR26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/mus.21713","volume":"42","author":"TM Burns","year":"2010","unstructured":"Burns TM. History of outcome measures for myasthenia gravis. Muscle Nerve. 2010;42(1):5\u201313.","journal-title":"Muscle Nerve"},{"issue":"2","key":"3406_CR27","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/mus.23296","volume":"46","author":"EH Mart\u00ednez-Lapiscina","year":"2012","unstructured":"Mart\u00ednez-Lapiscina EH, Erro ME, Ayuso T, Jeric\u00f3 I. Myasthenia gravis: sleep quality, quality of life, and disease severity. Muscle Nerve. 2012;46(2):174\u201380.","journal-title":"Muscle Nerve"},{"issue":"10","key":"3406_CR28","doi-asserted-by":"publisher","first-page":"e00538","DOI":"10.1002\/brb3.538","volume":"6","author":"S Hoffmann","year":"2016","unstructured":"Hoffmann S, Ramm J, Grittner U, Kohler S, Siedler J, Meisel A. Fatigue in myasthenia gravis: risk factors and impact on quality of life. Brain Behav. 2016;6(10):e00538.","journal-title":"Brain Behav"},{"issue":"6","key":"3406_CR29","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/mus.26695","volume":"60","author":"G Cutter","year":"2019","unstructured":"Cutter G, Xin H, Aban I, Burns TM, Allman PH, Farzaneh-Far R, et al. Cross-sectional analysis of the myasthenia gravis patient registry: disability and treatment. Muscle Nerve. 2019;60(6):707\u201315.","journal-title":"Muscle Nerve"},{"key":"3406_CR30","unstructured":"Fitzthum K. Lebensqualit\u00e4t bei myasthenia gravis. Klinische einflussfaktoren und langfristiger verlauf. Berlin, Germany: Charit\u00e9 - Universit\u00e4tsmedizin Berlin; 2015."},{"key":"3406_CR31","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","volume":"841","author":"RJ Barohn","year":"1998","unstructured":"Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci. 1998;841:769\u201372.","journal-title":"Ann N Y Acad Sci"},{"key":"3406_CR32","doi-asserted-by":"publisher","unstructured":"Besinger UA, Toyka KV, Heininger K, Fateh-Moghadam A, Schumm F, Sandel P, Long-term correlation of clinical course and acetylcholine receptor antibody in patients with myasthenia gravis. Ann N Y Acad Sci. 1981;377(1 Myasthenia Gr):812\u20135. https:\/\/doi.org\/10.1111\/j.1749-6632.1981.tb33781.x","DOI":"10.1111\/j.1749-6632.1981.tb33781.x"},{"key":"3406_CR33","doi-asserted-by":"crossref","unstructured":"Kuznetsova A, Brockhoff PB, Christensen RHB. lmerTest package: tests in linear mixed effects models. J Stat Softw. 2017;82(13). http:\/\/www.jstatsoft.org\/v82\/i13\/","DOI":"10.18637\/jss.v082.i13"},{"key":"3406_CR34","doi-asserted-by":"crossref","unstructured":"Bates D, M\u00e4chler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme. J Stat Softw. 2015;67(1). http:\/\/www.jstatsoft.org\/v67\/i01\/","DOI":"10.18637\/jss.v067.i01"},{"key":"3406_CR35","unstructured":"Therneau TM. A Package for survival analysis in S; 2015."},{"issue":"4","key":"3406_CR36","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1136\/jnnp.65.4.460","volume":"65","author":"N Murphy","year":"1998","unstructured":"Murphy N, Confavreux C, Haas J, K\u00f6nig N, Roullet E, Sailer M, et al. Quality of life in multiple sclerosis in France, Germany, and the United Kingdom. Cost of multiple sclerosis study group. J Neurol Neurosurg Psychiatry. 1998;65(4):460\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"3406_CR37","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/(SICI)1520-7560(199905\/06)15:3<205::AID-DMRR29>3.0.CO;2-O","volume":"15","author":"RR Rubin","year":"1999","unstructured":"Rubin RR, Peyrot M. Quality of life and diabetes. Diabetes Metab Res Rev. 1999;15(3):205\u201318.","journal-title":"Diabetes Metab Res Rev"},{"issue":"3","key":"3406_CR38","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1089\/109662103322144736","volume":"6","author":"ND Nelson","year":"2003","unstructured":"Nelson ND, Trail M, Van JN, Appel SH, Lai EC. Quality of life in patients with amyotrophic lateral sclerosis: perceptions, coping resources, and illness characteristics. J Palliat Med. 2003;6(3):417\u201324.","journal-title":"J Palliat Med"},{"issue":"9","key":"3406_CR39","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00415-010-5549-9","volume":"257","author":"Y Winter","year":"2010","unstructured":"Winter Y, Schepelmann K, Spottke AE, Claus D, Grothe C, Schr\u00f6der R, et al. Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurol. 2010;257(9):1473\u201381.","journal-title":"J Neurol"},{"issue":"5","key":"3406_CR40","doi-asserted-by":"publisher","first-page":"e511","DOI":"10.1212\/WNL.0000000000008747","volume":"94","author":"AF Lipka","year":"2020","unstructured":"Lipka AF, Boldingh MI, van Zwet EW, Schreurs MWJ, Kuks JBM, Tallaksen CM, et al. Long-term follow-up, quality of life, and survival of patients with Lambert-Eaton myasthenic syndrome. Neurology. 2020;94(5):e511\u201320.","journal-title":"Neurology"},{"issue":"6","key":"3406_CR41","first-page":"1375","volume":"33","author":"IZ Basta","year":"2012","unstructured":"Basta IZ, Pekmezovi\u0107 TD, Peri\u0107 SZ, Kisi\u0107-Tepav\u010devi\u0107 DB, Rako\u010devi\u0107-Stojanovi\u0107 VM, Stevi\u0107 ZD, et al. Assessment of health-related quality of life in patients with myasthenia gravis in Belgrade (Serbia). Neurol Sci off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2012;33(6):1375\u201381.","journal-title":"Neurol Sci off J Ital Neurol Soc Ital Soc Clin Neurophysiol"},{"issue":"2","key":"3406_CR42","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/mus.23398","volume":"46","author":"M Masuda","year":"2012","unstructured":"Masuda M, Utsugisawa K, Suzuki S, Nagane Y, Kabasawa C, Suzuki Y, et al. The MG-QOL15 Japanese version: validation and associations with clinical factors. Muscle Nerve. 2012;46(2):166\u201373.","journal-title":"Muscle Nerve"},{"issue":"7","key":"3406_CR43","doi-asserted-by":"publisher","first-page":"370","DOI":"10.6061\/clinics\/2016(07)03","volume":"71","author":"AM Mour\u00e3o","year":"2016","unstructured":"Mour\u00e3o AM, Gomez RS, Barbosa LSM, Freitas DdaS, Comini-Frota ER, Kummer A, et al. Determinants of quality of life in Brazilian patients with myasthenia gravis. Clin Sao Paulo Braz. 2016;71(7):370\u20134.","journal-title":"Clin Sao Paulo Braz"},{"issue":"1","key":"3406_CR44","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s12955-020-01549-z","volume":"18","author":"D Dong","year":"2020","unstructured":"Dong D, Chong MKC, Wu Y, Kaminski H, Cutter G, Xu X, et al. Gender differences in quality of life among patients with myasthenia gravis in China. Health Qual Life Outcomes. 2020;18(1):296.","journal-title":"Health Qual Life Outcomes"},{"issue":"12","key":"3406_CR45","doi-asserted-by":"publisher","first-page":"e1617","DOI":"10.1212\/WNL.0000000000010574","volume":"95","author":"M Mendoza","year":"2020","unstructured":"Mendoza M, Tran C, Bril V, Katzberg HD, Barnett C. Patient-acceptable symptom states in myasthenia gravis. Neurology. 2020;95(12):e1617\u201328.","journal-title":"Neurology"},{"key":"3406_CR46","doi-asserted-by":"publisher","first-page":"553626","DOI":"10.3389\/fneur.2020.553626","volume":"11","author":"P Szczudlik","year":"2020","unstructured":"Szczudlik P, Sobieszczuk E, Szyluk B, Lipowska M, Kubiszewska J, Kostera-Pruszczyk A. Determinants of quality of life in myasthenia gravis patients. Front Neurol. 2020;11:553626.","journal-title":"Front Neurol"},{"issue":"8","key":"3406_CR47","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.3390\/jcm11082189","volume":"11","author":"L Diez Porras","year":"2022","unstructured":"Diez Porras L, Homedes C, Alberti MA, Velez Santamaria V, Casasnovas C. Quality of life in myasthenia gravis and correlation of MG-QOL15 with other functional scales. J Clin Med. 2022;11(8):2189.","journal-title":"J Clin Med"},{"issue":"6","key":"3406_CR48","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1007\/s00415-021-10891-1","volume":"269","author":"S Lehnerer","year":"2022","unstructured":"Lehnerer S, Jacobi J, Schilling R, Grittner U, Marbin D, Gerischer L, et al. Burden of disease in myasthenia gravis: taking the patient\u2019s perspective. J Neurol. 2022;269(6):3050\u201363.","journal-title":"J Neurol"},{"key":"3406_CR49","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jns.2017.08.3250","volume":"381","author":"NFT Braz","year":"2017","unstructured":"Braz NFT, Rocha NP, Vieira \u00c9LM, Gomez RS, Kakehasi AM, Teixeira AL. Body composition and adipokines plasma levels in patients with myasthenia gravis treated with high cumulative glucocorticoid dose. J Neurol Sci. 2017;381:169\u201375.","journal-title":"J Neurol Sci"},{"key":"3406_CR50","doi-asserted-by":"crossref","unstructured":"Hafer-Macko C. Sarcopenic obesity in myasthenia gravis (P5.063). Neurology. 2015;84(14 Supplement):P5.063. Available from: http:\/\/n.neurology.org\/content\/84\/14_Supplement\/P5.063.abstract","DOI":"10.1212\/WNL.84.14_supplement.P5.063"},{"key":"3406_CR51","doi-asserted-by":"publisher","unstructured":"Mensink GBM, Schienkiewitz A, Haftenberger M, Lampert T, Ziese T, Scheidt-Nave C. \u00dcbergewicht und adipositas in Deutschland: ergebnisse der studie zur gesundheit erwachsener in Deutschland (DEGS1). Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 2013;56(5\u20136):786\u201394. https:\/\/doi.org\/10.1007\/s00103-012-1656-3","DOI":"10.1007\/s00103-012-1656-3"},{"key":"3406_CR52","doi-asserted-by":"publisher","unstructured":"Lee I, Kaminski HJ, Xin H, Cutter G. Gender and quality of life in myasthenia gravis patients from the myasthenia gravis foundation of America registry: gender and QOL in MG patients. Muscle Nerve. 2018;58(1):90\u20138. https:\/\/doi.org\/10.1002\/mus.26104","DOI":"10.1002\/mus.26104"},{"issue":"5","key":"3406_CR53","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/mus.27331","volume":"64","author":"JLS Thomsen","year":"2021","unstructured":"Thomsen JLS, Vinge L, Harbo T, Andersen H. Gender differences in clinical outcomes in myasthenia gravis: a prospective cohort study. Muscle Nerve. 2021;64(5):538\u201344.","journal-title":"Muscle Nerve"},{"issue":"1","key":"3406_CR54","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. Nat Rev Dis Primer. 2019;5(1):30.","journal-title":"Nat Rev Dis Primer"},{"issue":"20","key":"3406_CR55","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1212\/WNL.0000000000003339","volume":"87","author":"MI Boldingh","year":"2016","unstructured":"Boldingh MI, Maniaol AH, Brunborg C, Weedon-Fekj\u00e6r H, Verschuuren JJGM, Tallaksen CME. Increased risk for clinical onset of myasthenia gravis during the postpartum period. Neurology. 2016;87(20):2139\u201345.","journal-title":"Neurology"},{"issue":"6","key":"3406_CR56","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/mus.20734","volume":"35","author":"DE Stickler","year":"2007","unstructured":"Stickler DE, Stickler LL. Single-fiber electromyography during menstrual exacerbation and ovulatory suppression in MuSK antibody-positive myasthenia gravis. Muscle Nerve. 2007;35(6):808\u201311.","journal-title":"Muscle Nerve"},{"issue":"6","key":"3406_CR57","doi-asserted-by":"publisher","first-page":"e507","DOI":"10.1212\/NXI.0000000000000507","volume":"5","author":"I Lee","year":"2018","unstructured":"Lee I, Kaminski HJ, McPherson T, Feese M, Cutter G. Gender differences in prednisone adverse effects: survey result from the MG registry. Neurol Neuroimmunol Neuroinflamm. 2018;5(6):e507.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"3406_CR58","doi-asserted-by":"crossref","unstructured":"Wiendl H. Meisel A. Diagnostik und therapie myasthener syndrome, S2k-Leitlinie. DGN; 2022.","DOI":"10.1007\/s42451-023-00568-6"},{"key":"3406_CR59","doi-asserted-by":"publisher","unstructured":"Vu T, Meisel A, Mantegazza R, Annane D, Katsuno M, Aguzzi R. et al. Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid. 2022;1(5). https:\/\/doi.org\/10.1056\/EVIDoa2100066","DOI":"10.1056\/EVIDoa2100066"},{"key":"3406_CR60","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3389\/fimmu.2015.00176","volume":"6","author":"AE Nixon","year":"2015","unstructured":"Nixon AE, Chen J, Sexton DJ, Muruganandam A, Bitonti AJ, Dumont J, et al. Fully human monoclonal antibody inhibitors of the neonatal FC receptor reduce circulating IgG in non-human primates. Front Immunol. 2015;6:176.","journal-title":"Front Immunol"},{"issue":"10","key":"3406_CR61","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.tips.2018.07.007","volume":"39","author":"ES Ward","year":"2018","unstructured":"Ward ES, Ober RJ. Targeting FcRn to generate antibody-based therapeutics. Trends Pharmacol Sci. 2018;39(10):892\u2013904.","journal-title":"Trends Pharmacol Sci"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03406-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-023-03406-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03406-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T11:16:07Z","timestamp":1703330167000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-023-03406-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,10]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3406"],"URL":"https:\/\/doi.org\/10.1186\/s12883-023-03406-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2921061\/v1","asserted-by":"object"}]},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,10]]},"assertion":[{"value":"11 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"approval of the study by the Ethics Committee of the University Hospital G\u00f6ttingen was granted on October 16, 2017 (application number: 5\/2\/16) and on October 08, 2018 (application number: 6\/5\/18). All patients gave their written informed consent for the study participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"366"}}